CASE REPORTSWeekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombastheniaAndiç, Neslihan; Oğuz, Nur; Gündüz, Eren; Kiraz Bulduk, Tuba; Üsküdar Teke, HavaAuthor Information Hematology Division, Osmangazi University Medical School, Meşelik Campus, Eskişehir, Turkey Correspondence to Neslihan Andiç, Associate Professor, MD, Hematology Division, Osmangazi University Medical School, Meşelik Campus, Eskişehir, Turkey E-mail: [email protected] Received 21 July, 2020 Revised 30 January, 2021 Accepted 5 February, 2021 Blood Coagulation & Fibrinolysis: July 2021 - Volume 32 - Issue 5 - p 349-351 doi: 10.1097/MBC.0000000000001026 Buy Metrics Abstract Glanzmann thrombasthenia is an inherited disease causing bleeding episodes due to platelet dysfunction. The standard treatment for moderate-severe bleeding is platelet transfusion. Recombinant factor VIIa (rFVIIa) is successfully used in bleeding episodes and invasive procedures. Here, we present a patient with Glanzmann thrombasthenia, whose bleeding episodes could only be controlled by rFVIIa. The patient is a 28 years old male, who has had frequent bleeding episodes unresponsive to local hemostatic agents and tranexamic acid and had an anaphylactoid reaction to platelet transfusion. We started the patient on a low-dose (20 μg/kg) rFVIIa once a week. The patient has no spontaneous bleeding since then. This is the first case report of a Glanzmann thrombasthenia patient on routine prophylaxis with low-dose rFVIIa. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.